HRP20192164T1 - Postupak za aktiviranje i konjugiranje biomolekula - Google Patents
Postupak za aktiviranje i konjugiranje biomolekula Download PDFInfo
- Publication number
- HRP20192164T1 HRP20192164T1 HRP20192164TT HRP20192164T HRP20192164T1 HR P20192164 T1 HRP20192164 T1 HR P20192164T1 HR P20192164T T HRP20192164T T HR P20192164TT HR P20192164 T HRP20192164 T HR P20192164T HR P20192164 T1 HRP20192164 T1 HR P20192164T1
- Authority
- HR
- Croatia
- Prior art keywords
- coagulation factor
- conjugate
- agent
- activation
- activating
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 230000004913 activation Effects 0.000 title claims 2
- 230000021615 conjugation Effects 0.000 title 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 9
- 239000003114 blood coagulation factor Substances 0.000 claims 9
- 230000003213 activating effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical compound OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000009295 crossflow filtration Methods 0.000 claims 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical group SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 1
- 238000004255 ion exchange chromatography Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/025—Reverse osmosis; Hyperfiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (5)
1. Postupak za proizvodnju konjugata faktora koagulacije koji sadrži korake aktiviranja faktora koagulacije kontaktom sa sredstvo za aktiviranje; uklanjanje sredstva za aktiviranje; i
konjugiranje faktora koagulacije reakcijom faktora koagulacije s aktiviranim polimerom;
pri čemu su koraci postupka integrirani u integrirani sustav filtracije tangencijalnog strujanja, i,
pri čemu je polimer polietilen glikol, te
pri čemu je sredstvo za aktiviranje, redukcijsko sredstvo.
2. Postupak prema patentnom zahtjevu 1, naznačen time što nadalje obuhvaća korak odvajanja konjugata faktora koagulacije od ne konjugiranog faktora koagulacije.
3. Postupak prema patentnom zahtjevu 2, naznačen time što je konjugata faktora koagulacije odvojen od ne konjugiranog faktora koagulacije kromatografijom isključivanja po veličini ili kromatografijom s ionskom izmjenom.
4. Postupak prema jednom ili više zahtjeva 1 do 3, naznačen time što je faktor koagulacije rFVIII.
5. Postupak prema jednom ili više zahtjeva 1 do 4, naznačen time što je redukcijsko sredstvo ditiotreitol ili tris 2-karboksietil fosfin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30651310P | 2010-02-21 | 2010-02-21 | |
| EP11745404.1A EP2536399B1 (en) | 2010-02-21 | 2011-02-21 | Method for activation and conjugation of biomolecules |
| PCT/US2011/025592 WO2011103531A1 (en) | 2010-02-21 | 2011-02-21 | Method for Activation and Conjugation of Biomolecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192164T1 true HRP20192164T1 (hr) | 2020-03-06 |
Family
ID=44483343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192164TT HRP20192164T1 (hr) | 2010-02-21 | 2019-11-29 | Postupak za aktiviranje i konjugiranje biomolekula |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9254336B2 (hr) |
| EP (1) | EP2536399B1 (hr) |
| JP (1) | JP5726915B2 (hr) |
| KR (1) | KR101776976B1 (hr) |
| CN (2) | CN105664175B (hr) |
| AU (1) | AU2011217794B2 (hr) |
| BR (1) | BR112012020855B8 (hr) |
| CA (1) | CA2790401C (hr) |
| CL (1) | CL2012002306A1 (hr) |
| CO (1) | CO6592111A2 (hr) |
| CR (1) | CR20120437A (hr) |
| CU (1) | CU20120121A7 (hr) |
| CY (1) | CY1122711T1 (hr) |
| DK (1) | DK2536399T3 (hr) |
| EA (1) | EA201290804A1 (hr) |
| EC (1) | ECSP12012112A (hr) |
| ES (1) | ES2769629T3 (hr) |
| GT (1) | GT201200244A (hr) |
| HK (2) | HK1225652A1 (hr) |
| HR (1) | HRP20192164T1 (hr) |
| HU (1) | HUE047661T2 (hr) |
| IL (1) | IL221447A (hr) |
| LT (1) | LT2536399T (hr) |
| MX (1) | MX2012009674A (hr) |
| NZ (1) | NZ601905A (hr) |
| PE (1) | PE20130003A1 (hr) |
| PH (1) | PH12016501602A1 (hr) |
| PL (1) | PL2536399T3 (hr) |
| PT (1) | PT2536399T (hr) |
| RS (1) | RS59827B1 (hr) |
| SG (1) | SG183309A1 (hr) |
| SI (1) | SI2536399T1 (hr) |
| UA (1) | UA115221C2 (hr) |
| WO (1) | WO2011103531A1 (hr) |
| ZA (2) | ZA201206215B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE481323A (hr) * | 1947-04-10 | |||
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| ES2871418T3 (es) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Composiciones y métodos de conjugación de anticuerpos específicos de sitio |
| AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| SG11201604664PA (en) | 2013-12-12 | 2016-07-28 | Stemcentrx Inc | Novel anti-dpep3 antibodies and methods of use |
| US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120068769A (ko) * | 2002-07-15 | 2012-06-27 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도 |
| US7384909B2 (en) | 2002-07-15 | 2008-06-10 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents |
| MXPA05007163A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Derivados polimericos de acido maleamico y sus bioconjugados. |
| US20050175619A1 (en) * | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| PH12014500352A1 (en) * | 2004-11-12 | 2015-07-20 | Bayer Healthcare Llc | Site-directed modification of fviii |
| US20070173634A1 (en) * | 2006-01-24 | 2007-07-26 | Olsson Nils U | Methods for one-step purification of organic polymers using tangential flow filtration |
| US20080220448A1 (en) * | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| US8207298B2 (en) * | 2008-05-01 | 2012-06-26 | Archemix Corp. | Methods of separating biopolymer conjugated molecules from unconjugated molecules |
| CA2769326A1 (en) * | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
| AU2010334428B2 (en) * | 2009-12-22 | 2015-05-21 | Celldex Therapeutics, Inc. | Vaccine compositions |
-
2011
- 2011-02-21 CN CN201610094308.6A patent/CN105664175B/zh active Active
- 2011-02-21 EP EP11745404.1A patent/EP2536399B1/en active Active
- 2011-02-21 EA EA201290804A patent/EA201290804A1/ru unknown
- 2011-02-21 SG SG2012060083A patent/SG183309A1/en unknown
- 2011-02-21 DK DK11745404.1T patent/DK2536399T3/da active
- 2011-02-21 WO PCT/US2011/025592 patent/WO2011103531A1/en active Application Filing
- 2011-02-21 NZ NZ601905A patent/NZ601905A/en unknown
- 2011-02-21 PE PE2012001335A patent/PE20130003A1/es not_active Application Discontinuation
- 2011-02-21 PT PT117454041T patent/PT2536399T/pt unknown
- 2011-02-21 MX MX2012009674A patent/MX2012009674A/es active IP Right Grant
- 2011-02-21 KR KR1020127024535A patent/KR101776976B1/ko active IP Right Grant
- 2011-02-21 SI SI201131822T patent/SI2536399T1/sl unknown
- 2011-02-21 AU AU2011217794A patent/AU2011217794B2/en active Active
- 2011-02-21 US US13/580,102 patent/US9254336B2/en active Active
- 2011-02-21 PL PL11745404T patent/PL2536399T3/pl unknown
- 2011-02-21 RS RS20191568A patent/RS59827B1/sr unknown
- 2011-02-21 JP JP2012554081A patent/JP5726915B2/ja active Active
- 2011-02-21 CN CN201180020149.0A patent/CN102970988B/zh active Active
- 2011-02-21 HU HUE11745404A patent/HUE047661T2/hu unknown
- 2011-02-21 UA UAA201210994A patent/UA115221C2/uk unknown
- 2011-02-21 LT LTEP11745404.1T patent/LT2536399T/lt unknown
- 2011-02-21 ES ES11745404T patent/ES2769629T3/es active Active
- 2011-02-21 CA CA2790401A patent/CA2790401C/en active Active
- 2011-02-21 BR BR112012020855A patent/BR112012020855B8/pt active IP Right Grant
-
2012
- 2012-08-14 IL IL221447A patent/IL221447A/en active IP Right Grant
- 2012-08-17 ZA ZA2012/06215A patent/ZA201206215B/en unknown
- 2012-08-20 CL CL2012002306A patent/CL2012002306A1/es unknown
- 2012-08-20 GT GT201200244A patent/GT201200244A/es unknown
- 2012-08-21 EC ECSP12012112 patent/ECSP12012112A/es unknown
- 2012-08-21 CR CR20120437A patent/CR20120437A/es unknown
- 2012-08-21 CU CU2012000121A patent/CU20120121A7/es unknown
- 2012-08-21 CO CO12141192A patent/CO6592111A2/es unknown
-
2013
- 2013-08-21 HK HK16114174A patent/HK1225652A1/zh unknown
- 2013-08-21 HK HK13109759.7A patent/HK1182330A1/zh unknown
-
2014
- 2014-08-13 ZA ZA2014/05941A patent/ZA201405941B/en unknown
-
2016
- 2016-08-11 PH PH12016501602A patent/PH12016501602A1/en unknown
-
2019
- 2019-11-29 HR HRP20192164TT patent/HRP20192164T1/hr unknown
-
2020
- 2020-02-05 CY CY20201100113T patent/CY1122711T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192164T1 (hr) | Postupak za aktiviranje i konjugiranje biomolekula | |
| CY1122617T1 (el) | Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι | |
| AR057089A1 (es) | Procedimiento para la fabricacion de planchas de plastico celular | |
| DE502006006126D1 (de) | Verfahren zur herstellung wasserabsorbierender polymerpartikel | |
| FR2949907B1 (fr) | Procede de preparation d'un materiau composite pour electrode positive par extrusion en presence d'un solvant aqueux, electrode positive obtenue par le procede et applications | |
| WO2013050781A3 (en) | Process for the manufacture of shape memory polymer material | |
| RU2015120060A (ru) | Пористые частицы привитого сополимера, способ их получения и адсорбирующий материал, в котором они применяются | |
| GB201111609D0 (en) | Copolymers and membranes | |
| MA32484B1 (fr) | Procedes de separation par osmose directe | |
| MX2020014140A (es) | Metodo para purificar polimeros recuperados. | |
| WO2013074150A3 (en) | Mineral recovery in tailings using functionalized polymers | |
| WO2011069475A3 (en) | A method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof | |
| WO2014095608A3 (de) | Verfahren zur herstellung eines makromonomers | |
| GB2504641A (en) | Cross-linked poly-e-lysine particles | |
| WO2015071463A3 (de) | Herstellung von porösen materialien durch expansion von polymergelen | |
| PE20180759A1 (es) | Esferas polimericas macrorreticulares, metodo para prepararlas y metodo para el secuestro selectivo de iones metalicos y para recuperar oro con dichas esferas | |
| MX2013003456A (es) | Sintesis asistida por polimero de catalizador metalico soportado. | |
| EP2612746A3 (de) | Vorrichtung zur schichtweisen Herstellung von dreidimensionalen Objekten mittels rotierendem Auftrag | |
| CL2011003241A1 (es) | Metodo para separar material cargado de medio acuoso que comprende puesta en contacto del medio acuoso con polimero cationico donde dicho polimero comprende un polimero formado medinte reaccion de un aldehido y opcionalmente un compuesto reactivo de aldehido, en presencia de guanidina para proporcionar polimero con carga cationica neta. | |
| WO2009103018A3 (en) | Methods and kits for extraction of dna | |
| WO2010062683A3 (en) | Structure for molecular separations | |
| GB201211958D0 (en) | Multilayer filter gas turbine including a multilayer fitler and process of filtering | |
| EP2373638A4 (en) | POLYMER COMPOSITION AND DIALYSEMEMBRANE PRODUCED FROM THE POLYMER COMPOSITION | |
| EA201890994A1 (ru) | Пористый полимерный материал для связывания металлсодержащих ионов или для очистки органических молекул | |
| RU2014138971A (ru) | Получение молекулярно-импринтированных полимеров в результате сшивания |